FDA approves Izervay for geographic atrophy
Drug Discovery World
AUGUST 11, 2023
The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase III clinical trials. The FDA approval of Izervay is great news for the retina community and our patients suffering from GA.”
Let's personalize your content